<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="155244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078844</url>
  </required_header>
  <id_info>
    <org_study_id>NAM_MD_69</org_study_id>
    <nct_id>NCT01078844</nct_id>
  </id_info>
  <brief_title>Memantine in Adult Autism Spectrum Disorder</brief_title>
  <official_title>Memantine in Adult Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if memantine is helpful in managing problematic symptoms
      in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder NOS.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-Scale(CGI-S)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autism</condition>
  <condition>Asperger's Disorder</condition>
  <condition>Pervasive Developmental Disorder NOS</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment as usual plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>memantine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment as usual plus memantine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
    <description>memantine 5-20 mg daily</description>
    <arm_group_label>memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Look-alike placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Participant is currently in treatment in the JHBMC ASNC

          -  Participant has a diagnosis of:

          -  Autistic Disorder

          -  Asperger's Disorder

          -  PDD NOS

          -  Participant meets one of the following criteria:

          -  CGI-S &gt;= 4 (CGI-S: ________)

          -  Participant has the following problematic behaviors (at least one) that might be
             expected to benefit from memantine:

               1. _____________________________________________

               2. _____________________________________________

               3. _____________________________________________

        Exclusion criteria

        The patient meets none of the following criteria (mark if absent):

          -  Active seizures (Patients with a history of seizures, who have been seizure-free on
             an antiepileptic regimen for six months or more would be eligible).

          -  Rett's Syndrome or Childhood Disintegrative Disorder

          -  Active treatment with an acetylcholinesterase inhibitor

          -  Prior or current treatment with memantine

          -  Current treatment with lamotrigine

          -  Genetic, metabolic or degenerative disorder (excepting Fragile X).

          -  Brain malformation or known severe brain trauma

          -  Pregnancy or breastfeeding

          -  GFR &lt; 30 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Samstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 1, 2010</lastchanged_date>
  <firstreceived_date>March 1, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Eric Samstad, MD</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Asperger's Disorder</keyword>
  <keyword>Pervasive Developmental Disorder NOS</keyword>
  <keyword>Adult</keyword>
  <keyword>Memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
    <mesh_term>Developmental Disabilities</mesh_term>
    <mesh_term>Asperger Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
